Myriad Genetics, Inc. (NASDAQ:MYGN) is making waves at the 2025 ASCO Annual Meeting, presenting seven new research studies ...

Researchers at the National University of Singapore (NUS) have developed a scalable, non-viral technology that efficiently ...

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will share data from seven new research studies at the 2025 ASCO Annual Meeting, ...

The one-off treatment highlights the promise of a new type of gene editing and the challenges of using it to treat extremely ...

The researchers described the unprecedented speed of the oversight steps as being "through alternative procedures." In month ...

Scientists and medics have developed an ultra-rapid method of genetically diagnosing brain tumors that will cut the time it ...

The Crispr therapy was tailored to the baby’s specific condition and could provide a template for others.